BetterLife Pharma Clarifies CEO’s Share Ownership Amid BCSC Announcement

BetterLife Pharma ( (TSE:BETR) ) just unveiled an update.

BetterLife Pharma has addressed a recent British Columbia Securities Commission release by clarifying the beneficial ownership of shares by its CEO, Dr. Ahmad Doroudian. Since early 2023, Dr. Doroudian has increased his share ownership significantly through direct investment and salary settlements, reflecting his confidence in the company’s future and its lead asset, BETR-001. This development may impact BetterLife’s market perception and stakeholder confidence.

Spark’s Take on TSE:BETR Stock

According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.

BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.

To see Spark’s full report on TSE:BETR stock, click here.

More about BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds for neuro-psychiatric and neurological disorders. Their primary products include BETR-001, a non-hallucinogenic neuroplastogen for treating psychiatric and neurological disorders, and BETR-002, based on honokiol for anxiety-related disorders. The company is also exploring strategic alternatives for a drug candidate targeting viral infections.

Average Trading Volume: 46,903

Technical Sentiment Signal: Buy

Current Market Cap: C$14.25M

Find detailed analytics on BETR stock on TipRanks’ Stock Analysis page.